BABE-2014 — 5th World Congress on Bioavailabity and Bioequivalence: Pharmaceutical R&D Summit

29 Sep 2014 - 01 Oct 2014 Baltimore, United States

BABE-2014 is a scientific avenue for people from diversified Pharmaceutical backgrounds, Academic Institutions, Healthcare Institutes, Pharmaceutical Regulatory Agencies, Biotech and Clinical Research Organizations making the congress a desirable platform where participants can communicate and mutually get benefited by sharing experiences about their respective fields of interest, build collaborations with research organizations, acquire benefits from interactive workshops, promote innovative styles, trends and advancements of Bioavailability and Bioequivalence.

BABE-2014 — 5th World Congress on Bioavailabity and Bioequivalence: Pharmaceutical R&D Summit

29 Sep 2014 - 01 Oct 2014 Baltimore, United States

BABE-2014 is a scientific avenue for people from diversified Pharmaceutical backgrounds, Academic Institutions, Healthcare Institutes, Pharmaceutical Regulatory Agencies, Biotech and Clinical Research Organizations making the congress a desirable platform where participants can communicate and mutually get benefited by sharing experiences about their respective fields of interest, build collaborations with research organizations, acquire benefits from interactive workshops, promote innovative styles, trends and advancements of Bioavailability and Bioequivalence.

Discovery on Target

08 Oct 2014 - 10 Oct 2014  Boston, MA, United States

Cambridge Healthtech Institute will host its 12th Annual Discovery on Target event showcasing current and emerging "hot" targets for the pharmaceutical industry, October 8-10, 2014 in Boston, MA. Spanning three days, the meeting attracts over 900+ attendees (from 24 countries), composed of scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. In 2014 the event is comprised of 14 conference tracks which include Epigenetic Readers, Ubiquitin Proteasome, Big Data Discovery, GPCR Drug Discovery, RNAi-Screens-Functional-Genomics, PPI Targets, Protein-Targets, Histone-Methyltransferases-Demethylases, Drug Transporters, Maximizing Efficiency, GPCR Therapeutics, Genomics Screening, Cancer Metabolism and Membrane Production.

Discovery on Target

08 Oct 2014 - 10 Oct 2014  Boston, MA, United States

Cambridge Healthtech Institute will host its 12th Annual Discovery on Target event showcasing current and emerging "hot" targets for the pharmaceutical industry, October 8-10, 2014 in Boston, MA. Spanning three days, the meeting attracts over 900+ attendees (from 24 countries), composed of scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. In 2014 the event is comprised of 14 conference tracks which include Epigenetic Readers, Ubiquitin Proteasome, Big Data Discovery, GPCR Drug Discovery, RNAi-Screens-Functional-Genomics, PPI Targets, Protein-Targets, Histone-Methyltransferases-Demethylases, Drug Transporters, Maximizing Efficiency, GPCR Therapeutics, Genomics Screening, Cancer Metabolism and Membrane Production.

Discovery on Target

08 Oct 2014 - 10 Oct 2014  Boston, MA, United States

Cambridge Healthtech Institute will host its 12th Annual Discovery on Target event showcasing current and emerging "hot" targets for the pharmaceutical industry, October 8-10, 2014 in Boston, MA. Spanning three days, the meeting attracts over 900+ attendees (from 24 countries), composed of scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. In 2014 the event is comprised of 14 conference tracks which include Epigenetic Readers, Ubiquitin Proteasome, Big Data Discovery, GPCR Drug Discovery, RNAi-Screens-Functional-Genomics, PPI Targets, Protein-Targets, Histone-Methyltransferases-Demethylases, Drug Transporters, Maximizing Efficiency, GPCR Therapeutics, Genomics Screening, Cancer Metabolism and Membrane Production.

European Pharmaceutical Pricing & Reimbursement 13 - 14 October 2014, London UK

Our European Pharmaceutical Pricing & Reimbursement conference will be held on 13 & 14 October. Now in its 20th year, this event has been one of the oldest market leaders in the pharmaceutical industries calendar for some time.

Our expert speaking faculty; made up from key industry personnel from big pharma, biotech and academia will thoroughly explain and offer advice on P&R and market access. The 2014 agenda will focus on case studies as applied to different countries and environments in terms of market access.

European Pharmaceutical Pricing & Reimbursement 13 - 14 October 2014, London UK

Our European Pharmaceutical Pricing & Reimbursement conference will be held on 13 & 14 October. Now in its 20th year, this event has been one of the oldest market leaders in the pharmaceutical industries calendar for some time.

Our expert speaking faculty; made up from key industry personnel from big pharma, biotech and academia will thoroughly explain and offer advice on P&R and market access. The 2014 agenda will focus on case studies as applied to different countries and environments in terms of market access.

COPD: Novel Therapeutics and Management Strategies  20 - 21 October 2014, London UK

SMi is proud to to present it's 6th annual conference on COPD taking place from the 20th - 21st October 2014 in Central London. This year's conference will follow and expand on last year's event and will provide the audience with the latest updates and developemnts in the COPD industry both from pharmaceutical companies and academia alike.

According to the World Health Organisation (WHO), COPD is set to become the third leading cause of death worldwide by 2030. There is therefore an imperative need for all stakeholders to come together in order to tackle this disease. With the market for COPD growing year on year, new drug/compound development, innovation and management strategies are required to combat this disease. This conference will therefore bring togther major industry stakeholders within COPD to discuss, evaluate and review the latest development in the market.

This year's agenda will start with an overview of COPD while addressing the regulatory aspects and looking at market access. The focus will then be on managing exacerbation and comorbidities, enuring a successful clinical trial design and challenges in drug development. New sessions will be added, namely patient care, anxiety and depression in COPD, COPD and phenotyping and telehealth.

Hear the story from the other side: Jim & Mary Nelson have kindly accepted to share their story and battle with COPD. Don't miss the oppportunity to gain more insight from them

Orphan Drugs 20 - 21 October 2014, London UK

SMi are proud to present the 3rd Annual Orphan Drugs and Rare Diseases Conference.

The Orphan Drugs market is set to rise as a result of pharmaceutical companies now looking to orphan drugs as an essential revenue stream with 2014 set to be the year to see Orphan adoption!

As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access to Medicines Scheme was introduced. Key implementation of this will be a factor into further commercialization and developments.

With collaboration being a key topic of discussion, the conference will enable all those involved to discuss Market Access, Pricing and Reimbursement, Patient Engagement and Recruitment, with an insight into Regulatory Requirements.

SMi are providing a platform for all stakeholders, inclusive of small biotechs, pharmaceutical companies, patient advocacy organizations, researchers and regulators to share perspectives and expertise to drive the field of Orphan Drugs and Rare Diseases forward.

COPD: Novel Therapeutics and Management Strategies  20 - 21 October 2014, London UK

SMi is proud to to present it's 6th annual conference on COPD taking place from the 20th - 21st October 2014 in Central London. This year's conference will follow and expand on last year's event and will provide the audience with the latest updates and developemnts in the COPD industry both from pharmaceutical companies and academia alike.

According to the World Health Organisation (WHO), COPD is set to become the third leading cause of death worldwide by 2030. There is therefore an imperative need for all stakeholders to come together in order to tackle this disease. With the market for COPD growing year on year, new drug/compound development, innovation and management strategies are required to combat this disease. This conference will therefore bring togther major industry stakeholders within COPD to discuss, evaluate and review the latest development in the market.

This year's agenda will start with an overview of COPD while addressing the regulatory aspects and looking at market access. The focus will then be on managing exacerbation and comorbidities, enuring a successful clinical trial design and challenges in drug development. New sessions will be added, namely patient care, anxiety and depression in COPD, COPD and phenotyping and telehealth.

Hear the story from the other side: Jim & Mary Nelson have kindly accepted to share their story and battle with COPD. Don't miss the oppportunity to gain more insight from them

Orphan Drugs 20 - 21 October 2014, London UK

SMi are proud to present the 3rd Annual Orphan Drugs and Rare Diseases Conference.

The Orphan Drugs market is set to rise as a result of pharmaceutical companies now looking to orphan drugs as an essential revenue stream with 2014 set to be the year to see Orphan adoption!

As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access to Medicines Scheme was introduced. Key implementation of this will be a factor into further commercialization and developments.

With collaboration being a key topic of discussion, the conference will enable all those involved to discuss Market Access, Pricing and Reimbursement, Patient Engagement and Recruitment, with an insight into Regulatory Requirements.

SMi are providing a platform for all stakeholders, inclusive of small biotechs, pharmaceutical companies, patient advocacy organizations, researchers and regulators to share perspectives and expertise to drive the field of Orphan Drugs and Rare Diseases forward.

Point of Care Diagnostics - Market Opportunities and Technology Trends 27 - 28 October 2014, London UK

We present our 11th annual Point of Care conference due to be held on Monday 27 October and Tuesday 28 October 2014.

Our 2014 event will focus on the implementation including interoperability of technology and data management that is critical to the success of Point of Care Testing (POCT). Topics that will be examined include: ; enhancing quality in PoCT; trends in microfluidics for Health; industry standards; and how to protect IP.

There will be spotlight sessions on quality control and how to implement PoCT services strategically to make the event even more interactive and practical.

SMi will bring together PoC users, regulators, pharmaceutical and biotech companies and suppliers to discuss quality control, legislation, diagnostics, and the future of PoCT going forward. This event will feature expertise from diverse perspectives including over 16 Key Opinion Leaders.

Point of Care Diagnostics - Market Opportunities and Technology Trends 27 - 28 October 2014, London UK

We present our 11th annual Point of Care conference due to be held on Monday 27 October and Tuesday 28 October 2014.

Our 2014 event will focus on the implementation including interoperability of technology and data management that is critical to the success of Point of Care Testing (POCT). Topics that will be examined include: ; enhancing quality in PoCT; trends in microfluidics for Health; industry standards; and how to protect IP.

There will be spotlight sessions on quality control and how to implement PoCT services strategically to make the event even more interactive and practical.

SMi will bring together PoC users, regulators, pharmaceutical and biotech companies and suppliers to discuss quality control, legislation, diagnostics, and the future of PoCT going forward. This event will feature expertise from diverse perspectives including over 16 Key Opinion Leaders.

BABE-2014 — 5th World Congress on Bioavailabity and Bioequivalence: Pharmaceutical R&D Summit

29 Sep 2014 - 01 Oct 2014 Baltimore, United States

BABE-2014 is a scientific avenue for people from diversified Pharmaceutical backgrounds, Academic Institutions, Healthcare Institutes, Pharmaceutical Regulatory Agencies, Biotech and Clinical Research Organizations making the congress a desirable platform where participants can communicate and mutually get benefited by sharing experiences about their respective fields of interest, build collaborations with research organizations, acquire benefits from interactive workshops, promote innovative styles, trends and advancements of Bioavailability and Bioequivalence.